mTOR inhibitors seem to demonstrate better efficacy in renal cell carcinoma and breast cancer than in other malignancies, which is interesting as they share similar genetic alterations in the mTOR signaling pathway, including mutations to PI3KCA and mutations and deletions of phosphatase and tensin homolog (PTEN). Here, PTEN is linked to breast carcinoma.